New Synthetic Ibogaine Treats Addiction With Fewer Side Effects
A new version of synthetic ibogaine can treat opioid addiction but with a decreased risk of cardiac arrhythmias.
A new version of synthetic ibogaine can treat opioid addiction but with a decreased risk of cardiac arrhythmias.
Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.
The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).
Hope you guys enjoy this video!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock
Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.